Literature DB >> 22285670

Chemotherapy-associated angiogenesis in neuroblastoma tumors.

Martin Michaelis1, Nora Hinsch, U Ruth Michaelis, Florian Rothweiler, Thorsten Simon, Hans W ilhelm Doerr, Jaroslav Cinatl, Jindrich Cinatl.   

Abstract

The influences of cytotoxic drugs on endothelial cells remain incompletely understood. Herein, we examined the effects of chemotherapeutic agents in experimental angiogenesis models and analyzed vessel densities in clinical neuroblastoma tumor samples. Cisplatin (20 to 500 ng/mL), doxorubicin (4 to 100 ng/mL), and vincristine (0.5 to 4 ng/mL), drugs commonly involved in neuroblastoma therapy protocols, induced pro-angiogenic effects in different angiogenesis models. They enhanced endothelial cell tube formation, endothelial cell sprouting from spheroids, formation of tip cells in the sprouting assay, expression of αvβ3 integrin, and vitronectin binding. All three drugs increased global cellular kinase phosphorylation levels, including the angiogenesis-relevant molecules protein kinase Cβ and Akt. Pharmacological inhibition of protein kinase Cβ or Akt upstream of phosphatidylinositol 3-kinase reduced chemotherapy-induced endothelial cell tube formation. Moreover, the investigated chemotherapeutics dose dependently induced vessel formation in the chick chorioallantoic membrane assay. Tumor samples from seven high-risk patients with neuroblastoma were analyzed for vessel density by IHC. Results revealed that neuroblastoma samples taken after chemotherapy consistently showed an enhanced microvessel density compared with the corresponding samples taken before chemotherapy. In conclusion, our data show that chemotherapy can activate endothelial cells by inducing multiple pro-angiogenic signaling pathways and exert pro-angiogenic effects in vitro and in vivo. Moreover, we report a previously unrecognized clinical phenomenon that might, in part, be explained by our experimental observations: chemotherapy-associated enhanced vessel formation in tumors from patients with neuroblastoma.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285670     DOI: 10.1016/j.ajpath.2011.12.011

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  4 in total

1.  Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain.

Authors:  Elizabeth A Old; Suchita Nadkarni; John Grist; Clive Gentry; Stuart Bevan; Ki-Wook Kim; Adrian J Mogg; Mauro Perretti; Marzia Malcangio
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

2.  Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.

Authors:  Martin Michaelis; Bishr Agha; Florian Rothweiler; Nadine Löschmann; Yvonne Voges; Michel Mittelbronn; Tatjana Starzetz; Patrick N Harter; Behnaz A Abhari; Simone Fulda; Frank Westermann; Kristoffer Riecken; Silvia Spek; Klaus Langer; Michael Wiese; Wilhelm G Dirks; Richard Zehner; Jaroslav Cinatl; Mark N Wass; Jindrich Cinatl
Journal:  Sci Rep       Date:  2015-02-03       Impact factor: 4.379

3.  Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications.

Authors:  Mohammad Aslam Khan; Sanjeev K Srivastava; Arun Bhardwaj; Seema Singh; Sumit Arora; Haseeb Zubair; James E Carter; Ajay P Singh
Journal:  Oncotarget       Date:  2015-11-17

4.  Cinobufagin suppresses colorectal cancer angiogenesis by disrupting the endothelial mammalian target of rapamycin/hypoxia-inducible factor 1α axis.

Authors:  Xiaowu Li; Chunhui Chen; Yu Dai; Chengzhi Huang; Qinrui Han; Linlin Jing; Ye Ma; Yihua Xu; Yawei Liu; Liang Zhao; Junjiang Wang; Xuegang Sun; Xueqing Yao
Journal:  Cancer Sci       Date:  2019-03-29       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.